Cargando…
131. Antiviral NL-CVX1 Efficiently Blocks Infection of SARS-CoV-2 Viral Variants of Concern (VOC)
BACKGROUND: Using a computational approach, NL-CVX1 was developed by Neoleukin Therapeutics, Inc. to create a de novo protein that both blocks SARS-CoV-2 infection and is highly resilient to viral escape. In this study we evaluated the efficacy of NL-CVX1 against variants of the original SARS-CoV-2...
Autores principales: | Su, Wen, Walker, Matthew, Rebelo, Maria, Tang, Cong, Coelho, Ana R, Tatalick, Laurie, Riley, Marianne, Yu, Kevin, Blancas-Mejia, Luis M, Silva, Daniel-Adriano, Shoultz, David, Bernardes, Goncalo, Yen, Hui-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644688/ http://dx.doi.org/10.1093/ofid/ofab466.131 |
Ejemplares similares
-
De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Rebelo, Maria, et al.
Publicado: (2023) -
Cultural concerns in the use of coercion
por: Kastrup, Marianne
Publicado: (2007) -
A Selective SARS-CoV-2
Host-Directed Antiviral
Targeting Stress Response to Reactive Oxygen Species
por: Tang, Cong, et al.
Publicado: (2023) -
Antiviral Activities of Halogenated Emodin Derivatives against Human Coronavirus NL63
por: Horvat, Monika, et al.
Publicado: (2021) -
Molecular determinants of resistance in Escherichia coli-ST131 isolated blood stream infections
por: Hristea, Adriana, et al.
Publicado: (2013)